As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

After Pfizer declined to exercise its option to acquire AM-Pharma, the Dutch biotech has turned to European venture investors for a €116 million ($131 million) series C round to fund a Phase III study of recAP to treat acute kidney injury.

CEO Erik van den Berg told BioCentury that the all-European syndicate came together quickly, with first-time investors LSP and Andera Partners leading the round. “Investments close to home are relatively easier to conduct,” he said, although he added that the company is open to working with U.S.-based investors in the future...